Search Results - "ROSENBLATT, Joseph D"

Regulatory B cells in anti-tumor immunity by Zhang, Yu, Gallastegui, Nicolas, Rosenblatt, Joseph D

“…Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic…”
Get full text

B cell regulation of the anti-tumor response and role in carcinogenesis by Schwartz, Marc, Zhang, Yu, Rosenblatt, Joseph D.

“…The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic…”
Get full text

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study by PRO, Barbara, ADVANI, Ranjana, YIN YANG, SIEVERS, Eric L, KENNEDY, Dana A, SHUSTOV, Andrei, BRICE, Pauline, BARTLETT, Nancy L, ROSENBLATT, Joseph D, ILLIDGE, Tim, MATOUS, Jeffrey, RAMCHANDREN, Radhakrishnan, FANALE, Michelle, CONNORS, Joseph M

“…Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug…”
Get full text

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma by YOUNES, Anas, GOPAL, Ajay K, FORERO-TORRES, Andres, MOSKOWITZ, Craig H, CONNORS, Joseph M, ENGERT, Andreas, LARSEN, Emily K, KENNEDY, Dana A, SIEVERS, Eric L, CHEN, Robert, SMITH, Scott E, ANSELL, Stephen M, ROSENBLATT, Joseph D, SAVAGE, Kerry J, RAMCHANDREN, Radhakrishnan, BARTLETT, Nancy L, CHESON, Bruce D, DE VOS, Sven

“…Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing…”
Get full text

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma by Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L., Younes, Anas

“…We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory…”
Get full text

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma by ADVANI, Ranjana, FORERO-TORRES, Andres, FURMAN, Richard R, ROSENBLATT, Joseph D, YOUNES, Anas, HONG REN, HARROP, Kate, WHITING, Nancy, DRACHMAN, Jonathan G

“…To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell…”
Get full text

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma by Forero‐Torres, Andres, Leonard, John P., Younes, Anas, Rosenblatt, Joseph D., Brice, Pauline, Bartlett, Nancy L., Bosly, Andre, Pinter‐Brown, Lauren, Kennedy, Dana, Sievers, Eric L., Gopal, Ajay K.

“…Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic…”
Get full text

B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion by Zhang, Yu, Eliav, Yair, Shin, Seung-uon, Schreiber, Taylor H., Podack, Eckhard R., Tadmor, Tamar, Rosenblatt, Joseph D.

“…The mechanisms by which B lymphocytes inhibit anti-tumor immunity remain poorly understood. Murine EMT-6 mammary tumors grow readily in immune competent mice…”
Get full text

CD30: an important new target in hematologic malignancies by Deutsch, Yehuda E., Tadmor, Tamar, Podack, Eckhard R., Rosenblatt, Joseph D.

“…CD30 is abundantly and selectively expressed on the surface of Hodgkin Reed-Sternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid…”
Get full text

Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells by Shah, Sangeeta, Divekar, Anagha A., Hilchey, Shannon P., Cho, Hyun‐Mi, Newman, Corliss L., Shin, Seung‐Uon, Nechustan, Hovav, Challita‐Eid, Pia M., Segal, Benjamin M., Yi, Kyung Hee, Rosenblatt, Joseph D.

“…We investigated the role of B cells in tumor immunity by studying immune responses of mice genetically lacking B cells to primary tumors. IgM−/− B…”
Get full text

Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases by Shin, Seung-Uon, Cho, Hyun-Mi, Das, Rathin, Gil-Henn, Hava, Ramakrishnan, Sundaram, Al Bayati, Ahmed, Carroll, Stephen F, Zhang, Yu, Sankar, Ankita P, Elledge, Christian, Pimentel, Augustin, Blonska, Marzenna, Rosenblatt, Joseph D

“…Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. Metastasis is the major cause of TNBC mortality…”
Get full text

Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses by Zhang, Yu, Morgan, Richard, Chen, Chuan, Cai, Yancheng, Clark, Emily, Khan, Wasif Noor, Shin, Seung-Uon, Cho, Hyun-Mi, Al Bayati, Ahmed, Pimentel, Augustin, Rosenblatt, Joseph D

“…B lymphocytes play a role in inhibiting the immune response against certain tumors, but the underlying mechanisms are poorly understood. EMT-6 mammary tumors…”
Get full text

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma by Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham, Younes, Anas

“…Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin…”
Get full text

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma by Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L., Rosenblatt, Joseph D., Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M., Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M., Kennedy, Dana A., Shustov, Andrei

“…This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large…”
Get full text

Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response by Cho, Hyun-Mi, Rosenblatt, Joseph D, Tolba, Khaled, Shin, Sarah J, Shin, Daniel S, Calfa, Carmen, Zhang, Yu, Shin, Seung-Uon

“…NKG2D ligands link the innate and adapative immune response by activating the receptors expressed on effector cells of both the innate (NK) and adaptive immune…”
Get full text

Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement by Al Bayati, Ahmed, Plate, Thomas, Al Bayati, Mahmood, Yan, Yaohong, Lavi, Efrat Saraf, Rosenblatt, Joseph D.

“…Erdheim-Chester disease (ECD) is a rare form of non–Langerhans cell histiocytosis characterized by infiltration of organs by CD68+ and CD1a− lipid-laden…”
Get full text

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution by Alderuccio, Juan Pablo, Zhao, Wei, Desai, Amrita, Gallastegui, Nicolas, Ramdial, Jeremy, Kimble, Erik, de la Fuente, Macarena I, Rosenblatt, Joseph D, Chapman, Jennifer R, Vega, Francisco, Reis, Isildinha M, Lossos, Izidore S

“…Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large…”
Get full text

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies by FANALE, Michelle A, FORERO-TORRES, Andres, ROSENBLATT, Joseph D, ADVANI, Ranjana H, FRANKLIN, AnnaR, KENNEDY, Dana A, HAN, Tae H, SIEVERS, Eric L, BARTLETT, Nancy L

“…The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl…”
Get full text

The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model by Tadmor, Tamar, Zhang, Yu, Cho, Hyun-Mi, Podack, Eckhard R., Rosenblatt, Joseph D.

“…Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by…”
Get full text

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies by Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres

“…Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with…”
Get full text